SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis

BACKGROUND

The principal diagnosis/indication for this assessment is chronic diarrhoea due to bile acid malabsorption (BAM). Diarrhoea can be defined as the abnormal passage of loose or liquid stools more than three times daily and/or a daily stool weight > 200 g per day and is considered to be chronic if it persists for more than 4 weeks. The cause of chronic diarrhoea in adults is often difficult to ascertain and patients may undergo several investigations without a definitive cause being identified. BAM is one of several causes of chronic diarrhoea and results from failure to absorb bile acids (which are required for the absorption of dietary fats and sterols in the intestine) in the distal ileum.

OBJECTIVE

For people with chronic diarrhoea with unknown cause and in people with Crohn's disease and chronic diarrhoea with unknown cause (i.e. before resection): (1) What are the effects of selenium-75-homocholic acid taurine (SeHCAT) compared with no SeHCAT in terms of chronic diarrhoea, other health outcomes and costs? (2) What are the effects of bile acid sequestrants (BASs) compared with no BASs in people with a positive or negative SeHCAT test? (3) Does a positive or negative SeHCAT test predict improvement in terms of chronic diarrhoea, other health outcomes and costs?

DATA SOURCES

A systematic review was conducted to summarise the evidence on the clinical effectiveness of SeHCAT for the assessment of BAM and the measurement of bile acid pool loss. Search strategies were based on target condition and intervention, as recommended in the Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews in health care and the Cochrane Handbook for Diagnostic Test Accuracy Reviews. The following databases were searched up to April 2012: MEDLINE; MEDLINE In-Process & Other Non-Indexed Citations; EMBASE; the Cochrane Databases; Database of Abstracts of Reviews of Effects; Health Technology Assessment (HTA) Database; and Science Citation Index. Research registers and conference proceedings were also searched.

REVIEW METHODS

Systematic review methods followed the principles outlined in the CRD guidance for undertaking reviews in health care and the National Institute for Health and Care Excellence (NICE) Diagnostic Assessment Programme interim methods statement. In the health economic analysis, the cost-effectiveness of SeHCAT for the assessment of BAM, in patients with chronic diarrhoea, was estimated in two different populations. The first is the population of patients with chronic diarrhoea with unknown cause and symptoms suggestive of diarrhoea-predominant irritable bowel syndrome (IBS-D) and the second population concerns patients with Crohn's disease without ileal resection with chronic diarrhoea. For each population, three models were combined: (1) a short-term decision tree that models the diagnostic pathway and initial response to treatment (first 6 months); (2) a long-term Markov model that estimates the lifetime costs and effects for patients initially receiving BAS; and (3) a long-term Markov model that estimates the lifetime costs and effects for patients initially receiving regular treatment (IBS-D treatment in the first population and Crohn's treatment in the second population). Incremental cost-effectiveness ratios were estimated as additional cost per additional responder in the short term (first 6 months) and per additional quality-adjusted life-year (QALY) in the long term (lifetime).

RESULTS

We found three studies assessing the relationship between the SeHCAT test and response to treatment with cholestyramine. However, the studies had small numbers of patients with unknown cause chronic diarrhoea, and they used different cut-offs to define BAM. For the short term (first 6 months), when trial of treatment is not considered as a comparator, the optimal choice depends on the willingness to pay for an additional responder. For lower values (between £1500 and £4600) the choice will be no SeHCAT in all scenarios; for higher values either SeHCAT 10% or SeHCAT 15% becomes cost-effective. For the lifetime perspective, the various scenarios showed widely differing results: in the threshold range of £20,000-30,000 per QALY gained we found as optimal choice either no SeHCAT, SeHCAT 5% (only IBS-D) or SeHCAT 15%. When trial of treatment is considered a comparator, the analysis showed that for the short term, trial of treatment is the optimal choice across a range of scenarios. For the lifetime perspective with trial of treatment, again the various scenarios show widely differing results. Depending on the scenario, in the threshold range of £20,000-30,000 per QALY gained, we found as optimal choice either trial of treatment, no SeHCAT or SeHCAT 15%.

CONCLUSIONS

In conclusion, the various analyses show that for both populations considerable decision uncertainty exists and that no firm conclusions can be formulated about which strategy is optimal. Standardisation of the definition of a positive SeHCAT test should be the first step in assessing the usefulness of this test. As there is no reference standard for the diagnosis of BAM and SeHCAT testing provides a continuous measure of metabolic function, diagnostic test accuracy (DTA) studies are not the most appropriate study design. However, in studies where all patients are tested with SeHCAT and all patients are treated with BASs, response to treatment can provide a surrogate reference standard; further DTA studies of this type may provide information on the ability of SeHCAT to predict response to BASs. A potentially more informative option would be multivariate regression modelling of treatment response (dependent variable), with SeHCAT result and other candidate clinical predictors as covariates. Such a study design could also inform the definition of a positive SeHCAT result.

STUDY REGISTRATION

The study is registered as PROSPERO CRD42012001911.

FUNDING

The National Institute for Health Research Health Technology Assessment programme.

Incidental findings from clinical sequencing in Greece: reporting experts' attitudes

Unprecedented progress in sequencing technologies and decreasing cost have brought genomic testing into the clinical setting. At the same time, the debate in the literature concerning the return of incidental findings (IFs) has made this an important issue internationally. These developments reflect a shift in genetics that will also affect smaller countries, such as Greece, that are just starting to implement these technologies and may look to other countries for examples of good practice. Ten in-depth interviews were conducted with Greek experts in clinical sequencing. Previous experiences and attitudes toward IFs and clinical sequencing were investigated as well as views on the existing policy regarding managing genetic information generated through testing. . Interviews were analysed using thematic analysis. All participants reported the lack of any legal or other supportive mechanism. IFs are currently managed at a “local” level, i.e. within the clinic or the laboratory in an ad hoc way. All participants thought that clinically valid and actionable IFs should be returned, but always with caution and in respect to patients’ wishes, although several experts reported returning IFs according to their clinical discretion. Experts reported that most patients ask for all tests available but they felt that more counselling is needed to understand and manage genetic information. Due to the lack of any supporting mechanisms, professionals in Greece, even those with established experience in the field of genetic and genomic testing, have difficulties dealing with IFs. All experts agreed that it is now time, before the full integration of genomic testing into everyday clinical practice, for guidance to help Greek physicians work with patients and their families when IFs are discovered.

Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis

BACKGROUND

Premature birth is defined as birth of before 37 completed weeks' gestation. Not all pregnant women showing symptoms of preterm labour will go on to deliver before 37 weeks' gestation. Hence, addition of fetal fibronectin (fFN) testing to the diagnostic workup of women with suspected preterm labour may help to identify those women who do not require active management, and thus avoid unnecessary interventions, hospitalisations and associated costs.

OBJECTIVE

To assess the clinical effectiveness and cost-effectiveness of rapid fFN testing in predicting preterm birth (PTB) in symptomatic women.

DATA SOURCES

Bibliographic databases (including EMBASE, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials) were searched from 2000 to September/November 2011. Trial registers were also searched.

REVIEW METHODS

Systematic review methods followed published guidance; we assessed clinical effectiveness and updated a previous systematic review of test accuracy. Risk of bias was assessed using the Cochrane tool (randomised controlled trials; RCTs) and a modification of QUADAS-2 (diagnostic test accuracy studies; DTAs). Summary risk ratios or weighted mean difference were calculated using random-effects models. Summary sensitivity and specificity used a bivariate summary receiver operating characteristic model. Heterogeneity was investigated using subgroup and sensitivity analyses. Health economic analysis focused on cost consequences. The time horizon was hospital admission for observation. A main structural assumption was that, compared with usual care, fFN testing doesn't increase adverse events or negative pregnancy outcomes.

RESULTS

Five RCTs and 15 new DTAs were identified. No RCT reported significant effects of fFN testing on maternal or neonatal outcomes. One study reported a subgroup analysis of women with negative fFN test observed > 6 hours, which showed a reduction in length of hospital stay where results were known to clinicians. Combining data from new studies and the previous systematic review, the pooled estimates of sensitivity and specificity were: 76.7% and 82.7% for delivery within 7-10 days of testing; 69.1% and 84.4% for delivery < 34 weeks' gestation; and 60.8% and 82.3% for delivery < 37 weeks' gestation. Estimates were similar across all subgroups sensitivity analyses. The base-case cost analysis resulted in a cost saving of £23.87 for fFN testing compared with usual care. The fFN testing was cost-neutral at an approximate cost of £45. Probabilistic sensitivity analysis gave an incremental cost (saving) of -£25.59 (97.5% confidence interval -£304.96 to £240.06), indicating substantial uncertainty. Sensitivity analyses indicated that admission rate had the largest impact on results.

CONCLUSIONS

Fetal fibronectin testing has moderate accuracy for predicting PTB. The main potential role is likely to be reducing health-care resource usage by identifying women not requiring intervention. Evidence from RCTs suggests that fFN does not increase adverse outcomes and may reduce resource use. The base-case analysis showed a modest cost difference in favour of fFN testing, which is largely dependent on whether or not fFN testing reduces hospital admission. Currently, there are no high-quality studies and the existing trials were generally underpowered. Hence, there is a need for high-quality adequately powered trials using appropriate study designs to confirm the findings presented.

STUDY REGISTRATION

PROSPERO 2011:CRD42011001468. Available from www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42011001468.

FUNDING

The National Institute for Health Research Health Technology Assessment programme.

Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique

This study compared in vivo levels of the antioxidant glutathione (GSH) in the motor cortex of 11 ALS patients with those in 11 age-matched healthy volunteers (HV). Using the standard J-edited spin-echo difference MRS technique, GSH spectra were recorded on a 3.0 T GE MR system from a single precentral gyrus voxel. GSH levels expressed as ratios to the unsuppressed voxel tissue water (W) were 31% lower in ALS patients than in HV (p=.005), and 36% lower in ALS than in HV (p=.02) when expressed as ratios to the total creatine peak (tCr), supporting a role for oxidative stress in ALS. Levels of the putative neuronal marker N-acetylaspartate (NAA) relative to W did not differ between ALS and HV (p=.26), but were lower by 9% in ALS than in HV (p=.013) when expressed as ratios relative to tCr. This discrepancy is attributed to small but opposite changes in NAA and tCr in ALS that, as a ratio, resulted in a statistically significant group difference, further suggesting caution in using tCr as an internal reference under pathological conditions.

A systematic review and cost-effectiveness analysis of specialist services and adrenaline auto-injectors in anaphylaxis

BACKGROUND

Anaphylaxis is a severe, life-threatening generalised or systemic hypersensitivity reaction with high mortality. Specialist services (SSs) are believed to reduce anaphylaxis recurrence and improve use of adrenaline injectors (AIs), which can reduce mortality if used correctly and in time.

OBJECTIVES

To review the evidence on which persons are at high risk of anaphylactic episodes, the effects of history-taking (including signs, symptoms and physical examination) for anaphylaxis, and when (suspected) patients should be referred. To assess the cost-effectiveness of SS compared with standard care (SC) with or without prescription of AIs.

DATA SOURCES

In order to assess the clinical effectiveness, 10 databases [Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA), NHS Economic Evaluation Database (NHS EED), Science Citation Index (SCI), Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, from inception up to March 2011] were searched without data restriction in order to identify relevant studies [randomised controlled trials (RCTs), controlled clinical trials, observational studies, prognostic studies using a multivariate model] written in English.

REVIEW METHODS

Standard review methods were applied for the assessment of clinical effectiveness. A Markov model, validated by clinical experts, was constructed, which modelled anaphylaxis according to trigger: either food, drug, insect or idiopathic. Anaphylaxis mortality was modelled as a function of time to die and time for emergency response. Probabilistic sensitivity analysis on key parameters was performed.

RESULTS

From the systematic review, 11,058 references were identified by the searches for studies assessing the clinical effectiveness. In total, 107 papers were obtained, and five prospective observational studies, including 1725 patients, were included. These studies estimated the risk of recurrence to be between 30% and 42.8%. In children (< 12 years), an overall recurrence of 27% was reported, with food being the most frequent allergen (71%). From the cost-effectiveness analysis (CEA), SC with injectors was dominated by SS with or without injectors. SS with no injectors would be cost-effective if the threshold for a quality-adjusted life-year (QALY) was greater than about £ 740 and with injectors would be cost-effective if the threshold was > £ 1800. These results were robust to all sensitivity analyses except at relatively extreme values of a small number of parameters.

LIMITATIONS

Limitations of the study include the low yield from the systematic review; in particular there were no good-quality studies of either SSs or AI effectiveness. This implied a great reliance on expert opinion in the CEA. However, this was appropriately addressed using sensitivity analysis.

CONCLUSIONS

Only five observational studies assessing clinical effectiveness were identified. Owing to the lack of good data to inform the effectiveness of anaphylaxis intervention, we recommend considerations of RCTs or at least well-designed observational studies of the components of care in SSs. The results of the CEA showed that SS with AIs was cost-effective at a threshold of £ 20,000 per QALY. More well-designed prospective studies on the effectiveness of SSs are needed to confirm these findings.

Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis

BACKGROUND

Medical imaging techniques are important in the management of many patients with liver disease. Unenhanced ultrasound examinations sometimes identify focal abnormalities in the liver that may require further investigation, primarily to distinguish liver cancers from benign abnormalities. One important factor in selecting an imaging test is the ability to provide a rapid diagnosis. Options for additional imaging investigations include computed tomography (CT) and/or magnetic resonance imaging (MRI) and biopsy when the diagnosis remains uncertain. CT and MRI usually require referral with associated waiting time and are sometimes contraindicated. The use of contrast agents may improve the ability of ultrasound to distinguish between liver cancer and benign abnormalities and, because it can be performed at the same appointment as unenhanced ultrasound, more rapid diagnoses may be possible.

OBJECTIVE

To compare the clinical effectiveness and cost-effectiveness of contrast-enhanced ultrasound (CEUS) using SonoVue(®) with that of contrast-enhanced computed tomography (CECT) and contrast-enhanced magnetic resonance imaging (CEMRI) for the assessment of adults with focal liver lesions (FLLs) in whom previous liver imaging is inconclusive.

DATA SOURCES

Eight bibliographic databases including MEDLINE, EMBASE, Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects were searched from 2000 to September/October 2011. Research registers and conference proceedings were also searched.

REVIEW METHODS

Systematic review methods followed published guidance. Risk of bias was assessed using a modified version of the QUADAS-2 tool. Results were stratified by clinical indication for imaging (characterisation of FLLs detected on ultrasound surveillance of cirrhosis patients, detection of liver metastases, characterisation of incidentally detected FLLs, assessment of treatment response). For incidental FLLs, pooled estimates of sensitivity and specificity, with 95% CIs, were calculated using a random-effects model. For other clinical indications a narrative summary was used. The cost-effectiveness of CEUS was modelled separately for the three main clinical applications considered [characterisation of FLLs detected on ultrasound surveillance of cirrhosis patients, detection of liver metastases in patients with colorectal cancer (CRC), characterisation of incidentally detected FLLs].

RESULTS

Of the 854 references identified, 19 (describing 18 studies) were included in the review. Hand searching of conference proceedings identified a further three studies. Twenty of the 21 studies included in the systematic review were diagnostic test accuracy studies. Studies in cirrhosis patients reported varying estimates of test performance. There was no consistent evidence of a significant difference in performance between imaging modalities. It was unclear whether or not CEUS alone is adequate to rule out hepatocellular carcinoma (HCC) for FLLs of < 30 mm; one study indicated that CEUS may be better at ruling out HCC for FLLs of 11-30 mm [very small FLLs (< 10 mm) excluded]. There was no consistent evidence of a difference in test performance between imaging modalities for the detection of metastases; CEUS alone may be adequate to rule out liver metastases in colorectal cancer. In patients with incidentally detected FLLs, the pooled estimates of sensitivity for any malignancy using CEUS and CECT were 95.1% and 94.6%, respectively, and the corresponding specificity estimates were 93.8% and 93.1% respectively. One study comparing CEUS with CEMRI reported similar sensitivity and lower specificity for both modalities. In the surveillance of cirrhosis, CEUS was as effective as but £379 less costly than CECT. CEMRI was £1063 more costly than CEUS and gained 0.022 QALYs. In the detection of liver metastases from CRC, CEUS cost £1 more than CECT, and at a lifetime time horizon they yielded equal QALYs. CEMRI was dominated by CECT. In the characterisation of incidentally detected FLLs, CEUS was slightly more effective than CECT and CEMRI (by 0.0002 QALYs and 0.0026 QALYs respectively) and less costly (by £52 and £131 respectively).

LIMITATIONS

There were a number of methodological issues specific to the studies included in this review. The main indication for liver imaging in the populations considered is likely to be to rule out primary liver cancer or metastases. Therefore, patient-level analyses of test performance are of particular interest. Some of the studies included in this review reported per-patient analyses; however, no study clearly stated how results were defined (e.g. was the presence of any positive lesion regarded as a positive test for the whole patient). In addition, a number of studies reported data for one lesion per patient (treated as per-patient data in this assessment). These studies generally selected the largest lesion or the lesion 'most suspicious for malignancy' for inclusion in analyses, with the consequence that estimates of test performance may have been exaggerated. The applicability of studies included in this review may be limited, as the majority of imaging studies were interpreted by multiple, experienced operators and the prevalence of malignancy in included studies appeared higher than might be expected in clinical practice. The cost-effectiveness analyses did not take into account the potential benefits of reduced anxiety that may arise from potentially shorter waiting times associated with SonoVue CEUS.

CONCLUSIONS

SonoVue CEUS could provide similar diagnostic performance to other imaging modalities (CECT and CEMRI) for the assessment of FLLs. Economic analyses indicated that CEUS was a cost-effective replacement for CEMRI. The use of CEUS instead of CECT was considered cost-effective in the surveillance of cirrhosis and the characterisation of incidentally detected FLLs, with similar costs and effects for the detection of liver metastases from CRC. Further research is needed to compare the effects of different imaging modalities (SonoVue CEUS, CECT, CEMRI) on therapeutic planning, treatment and clinical outcomes. Future test accuracy studies should provide standardised definitions of a positive imaging test, and compare all three imaging modalities in the same patient group.

STUDY REGISTRATION

PROSPERO: CRD42011001694.

FUNDING

The National Institute for Health Research Health Technology Assessment programme.

A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD

BACKGROUND

Computed tomography (CT) is important in diagnosing and managing many conditions, including coronary artery disease (CAD) and congenital heart disease. Current CT scanners can very accurately diagnose CAD requiring revascularisation in most patients. However, imaging technologies have developed rapidly and new-generation computed tomography (NGCCT) scanners may benefit patients who are difficult to image (e.g. obese patients, patients with high or irregular heart beats and patients who have high levels of coronary calcium or a previous stent or bypass graft).

OBJECTIVE

To assess the clinical effectiveness and cost-effectiveness of NGCCT for diagnosing clinically significant CAD in patients who are difficult to image using 64-slice computed tomography and treatment planning in complex congenital heart disease.

DATA SOURCES

Bibliographic databases were searched from 2000 to February/March 2011, including MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), NHS Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA) database and Science Citation Index (SCI). Trial registers and conference proceedings were searched.

REVIEW METHODS

Systematic review methods followed published guidance. Risk of bias was assessed using QUADAS-2. Results were stratified by patient group. Summary sensitivity and specificity were calculated using a bivariate summary receiver operating characteristic, or random effects model. Heterogeneity was assessed using the chi-squared statistic and I(2)-statistic. Cost-effectiveness of NGCCT was modelled separately for suspected and known CAD, evaluating invasive coronary angiography (ICA) only, ICA after positive NGCCT (NGCCT-ICA), and NGCCT only. The cost-effectiveness of NGCCT, compared with 64-slice CT, in reducing imaging-associated radiation in congenital heart disease was assessed.

RESULTS

Twenty-four studies reported accuracy of NGCCT for diagnosing CAD in difficult-to-image patients. No clinical effectiveness studies of NGCCT in congenital heart disease were identified. The pooled per-patient estimates of sensitivity were 97.7% [95% confidence interval (CI) 88.0% to 99.9%], 97.7% (95% CI 93.2% to 99.3%) and 96.0% (95% CI 88.8% to 99.2%) for patients with arrhythmias, high heart rates and previous stent, respectively. The corresponding estimates of specificity were 81.7% (95% CI 71.6% to 89.4%), 86.3% (95% CI 80.2% to 90.7%) and 81.6% (95% CI 74.7% to 87.3%), respectively. In patients with high coronary calcium scores, previous bypass grafts or obesity, only per-segment or per-artery data were available. Sensitivity estimates remained high (> 90% in all but one study). In patients with suspected CAD, the NGCCT-only strategy appeared most cost-effective; the incremental cost-effectiveness ratio (ICER) of NGCCT-ICA compared with NGCCT only was £71,000. In patients with known CAD, the most cost-effective strategy was NGCCT-ICA (highest cost saving, dominates ICA only). The ICER of NGCCT only compared with NGCCT-ICA was £726,230. For radiation exposure only, the ICER for NGCCT compared with 64-slice CT in congenital heart disease ranged from £521,000 for the youngest patients to £90,000 for adults.

LIMITATIONS

Available data were limited, particularly for obese patients and patients with previous bypass grafts. All studies of the accuracy of NGCCT assume that the reference standard (ICA) is 100% sensitive and specific; however, there is some evidence that ICA may sometimes underestimate the extent and severity of stenosis. Patients with more than one criterion that could contribute to difficulty in imaging were often excluded from studies; the effect on test accuracy of multiple difficult to image criteria remains uncertain.

CONCLUSIONS

NGCCT may be sufficiently accurate to diagnose clinically significant CAD in some or all difficult-to-image patient groups. Economic analyses suggest that NGCCT is likely to be considered cost-effective for difficult-to-image patients with CAD, at current levels of willingness to pay in the NHS. For patients with suspected CAD, NGCCT only would be most favourable; for patients with known CAD, NGCCT-ICA would be most favourable. No studies assessing the effects of NGCCT on therapeutic decision making, or subsequent patient outcomes, were identified. The ideal study to address these questions would be a large multi-centre RCT. However, one possible alternative might be to establish a multicentre tracker study. High-quality test accuracy studies, particularly in obese patients, patients with high coronary calcium, and those with previous bypass grafts are needed to confirm the findings of our systematic review. These studies should include patients with multiple difficult to image criteria.

FUNDING

The National Institute for Health Research Health Technology Assessment programme. This project was funded by the HTA programme, on behalf of NICE, as project number 10/107/01.

Standard- or high-dose oxytocin for nulliparous women with confirmed delay in labour: quantitative and qualitative results from a pilot randomised controlled trial

OBJECTIVE

Evidence suggests that a high dose of oxytocin for nulliparous women at 37-42 weeks of gestation with confirmed delay in labour increases spontaneous vaginal birth. We undertook a pilot study to test the feasibility of this treatment.

DESIGN

Pilot double-blind randomised controlled trial.

SETTING

Three teaching hospitals in the UK.

POPULATION

A total of 94 consenting nulliparous women at term with confirmed delay in labour were recruited, and 18 were interviewed.

METHODS

Women were assigned to either a standard (2 mU/min, increasing every 30 minutes to 32 mU/minute) or a high-dose regimen (4 mU/minute, increasing every 30 minutes to 64 mU/minutes) oxytocin by computer-generated randomisation. Simple descriptive statistics were used, as the sample size was insufficient to evaluate clinical outcomes. The constant comparative method was used to analyse the interviews.

MAIN OUTCOMES MEASURES

The main outcome measures: number of women eligible; maternal and neonatal birth; safety; maternal psychological outcomes and experiences; health-related quality of life outcomes using validated tools and data on health service resource use; incidence of suspected delay of labour (cervical dilatation of <2 cm after 4 hours, once labour is established); and incidence of confirmed delay of labour (progress of <1 cm on repeat vaginal examination after a period of 2 hours).

RESULTS

We successfully developed systems to recruit eligible women in labour and to collect data. Rates of spontaneous vaginal birth (10/47 versus 12/47, RR 1.2, 95% CI 0.6-2.5) and caesarean section (15/47 versus 17/47, RR 1.1, 95% CI 0.6-2.0) were increased, and rates of instrumental birth were reduced (21/47 versus 17/47, RR 0.8, 95% CI 0.5-1.3). No evidence of increased harm for either mother or baby was found. The incidences of suspected delay (14%) and confirmed delay (11%) in labour were less than anticipated. Of those who did not go on to have delayed labour confirmed, all except one woman gave birth vaginally.

CONCLUSIONS

A pilot trial assessing the efficacy of high-dose oxytocin was feasible, but uncertainty remains, highlighting the need for a large definitive trial. The implementation of national guidance of suspected and confirmed delay in labour is likely to reduce intervention.

First isolation of Mimivirus in a patient with pneumonia

BACKGROUND

Mimiviridae Mimivirus, including the largest known viruses, multiply in amoebae. Mimiviruses have been linked to pneumonia, but they have never been isolated from patients. To further understand the pathogenic role of these viruses, we aimed to isolate them from a patient presenting with pneumonia.

METHODS

We cultured, on Acanthamoeba polyphaga amoebae, pulmonary samples from 196 Tunisian patients with community-acquired pneumonia during the period 2009-2010. An improved technique was used for Mimivirus isolation, which used agar plates where the growth of giant viruses is revealed by the formation of lysis plaques. Mimivirus serology was tested by microimmunofluorescence and by bidimensional immunoproteomic analysis using Mimivirus strains, to identify specific immunoreactive proteins. The new Mimivirus strain genome sequencing was performed on Roche 454 GS FLX Titanium, then AB SOLiD instruments.

RESULTS

We successfully isolated a Mimivirus (LBA111), the largest virus ever isolated in a human sample, from a 72-year-old woman presenting with pneumonia. Electron microscopy revealed a Mimivirus-like virion with a size of 554 ± 10 nm. The LBA111 genome is 1.23 megabases, and it is closely related to that of Megavirus chilensis. Furthermore, the serum from the patient reacted specifically to the virus compared to controls.

CONCLUSIONS

This is the first Mimivirus isolated from a human specimen. The findings presented above together with previous works establish that mimiviruses can be associated with pneumonia. The common occurrence of these viruses in water and soil makes them probable global agents that are worthy of investigation.

Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer

BACKGROUND

Complete surgical removal of the prostate, radical prostatectomy, is the most frequently used treatment option for men with localised prostate cancer. The use of laparoscopic (keyhole) and robot-assisted surgery has improved operative safety but the comparative effectiveness and cost-effectiveness of these options remains uncertain.

OBJECTIVE

This study aimed to determine the relative clinical effectiveness and cost-effectiveness of robotic radical prostatectomy compared with laparoscopic radical prostatectomy in the treatment of localised prostate cancer within the UK NHS.

DATA SOURCES

MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, BIOSIS, Science Citation Index and Cochrane Central Register of Controlled Trials were searched from January 1995 until October 2010 for primary studies. Conference abstracts from meetings of the European, American and British Urological Associations were also searched. Costs were obtained from NHS sources and the manufacturer of the robotic system. Economic model parameters and distributions not obtained in the systematic review were derived from other literature sources and an advisory expert panel.

REVIEW METHODS

Evidence was considered from randomised controlled trials (RCTs) and non-randomised comparative studies of men with clinically localised prostate cancer (cT1 or cT2); outcome measures included adverse events, cancer related, functional, patient driven and descriptors of care. Two reviewers abstracted data and assessed the risk of bias of the included studies. For meta-analyses, a Bayesian indirect mixed-treatment comparison was used. Cost-effectiveness was assessed using a discrete-event simulation model.

RESULTS

The searches identified 2722 potentially relevant titles and abstracts, from which 914 reports were selected for full-text eligibility screening. Of these, data were included from 19,064 patients across one RCT and 57 non-randomised comparative studies, with very few studies considered at low risk of bias. The results of this study, although associated with some uncertainty, demonstrated that the outcomes were generally better for robotic than for laparoscopic surgery for major adverse events such as blood transfusion and organ injury rates and for rate of failure to remove the cancer (positive margin) (odds ratio 0.69; 95% credible interval 0.51 to 0.96; probability outcome favours robotic prostatectomy = 0.987). The predicted probability of a positive margin was 17.6% following robotic prostatectomy compared with 23.6% for laparoscopic prostatectomy. Restriction of the meta-analysis to studies at low risk of bias did not change the direction of effect but did decrease the precision of the effect size. There was no evidence of differences in cancer-related, patient-driven or dysfunction outcomes. The results of the economic evaluation suggested that when the difference in positive margins is equivalent to the estimates in the meta-analysis of all included studies, robotic radical prostatectomy was on average associated with an incremental cost per quality-adjusted life-year that is less than threshold values typically adopted by the NHS (£30,000) and becomes further reduced when the surgical capacity is high.

LIMITATIONS

The main limitations were the quantity and quality of the data available on cancer-related outcomes and dysfunction.

CONCLUSIONS

This study demonstrated that robotic prostatectomy had lower perioperative morbidity and a reduced risk of a positive surgical margin compared with laparoscopic prostatectomy although there was considerable uncertainty. Robotic prostatectomy will always be more costly to the NHS because of the fixed capital and maintenance charges for the robotic system. Our modelling showed that this excess cost can be reduced if capital costs of equipment are minimised and by maintaining a high case volume for each robotic system of at least 100-150 procedures per year. This finding was primarily driven by a difference in positive margin rate. There is a need for further research to establish how positive margin rates impact on long-term outcomes.

FUNDING

The National Institute for Health Research Health Technology Assessment programme.

Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis

OBJECTIVE

To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antagonists (eptifibatide and abciximab). Results were analysed by drug administration with planned percutaneous coronary intervention (PCI) or as medical management without planned PCI, and separately for STEMI or NSTE ACS patients.

RESEARCH DESIGN AND METHODS

A systematic review was performed of randomized controlled trials of tirofiban, abciximab, eptifibatide or usual care given to patients with acute coronary syndrome. Nine databases were searched up to March 2010. Pair-wise meta-analysis was used to combine all available direct comparisons; indirect comparisons and network analysis were performed when this was not possible. The primary outcome was MACE (major adverse cardiac event).

RESULTS

The search yielded 8, 119 records and 50 trials were included (total number of patients = 52,958). Compared to usual care, high and medium-dose tirofiban (25 and 10 µg/kg/min) administered with planned PCI reduced MACE at 30 days for patients with STEMI (RR 0.67, 95% CI 0.45, 0.99; RR 0.28, 95% CI 0.10, 0.80), but was not effective as a medical management. Medium-dose tirofiban (10 µg/kg/min) administered with planned PCI or low dose (0.4 µg/kg/min) as medical management reduced the risk of MACE for patients with NSTE ACS (RR 0.39, 95% CI 0.21, 0.75; RR 0.58, 95% CI 0.41, 0.83) in comparison to usual care, but at the expense of increased thrombocytopenia (RR 3.26, 95% CI 1.31, 8.13). Evidence from RCTs and network analysis indicated tirofiban and abciximab were equally effective and safe. Comparing tirofiban and eptifibatide treatment by indirect and network analysis produced inconclusive results.

CONCLUSIONS

Tirofiban was more effective than usual care for STEMI and NSTE ACS patients receiving planned PCI, and NSTE ACS patients receiving medical management. Tirofiban and abciximab were equally effective. Comparisons of tirofiban and eptifibatide were inconclusive.

Randomised preference trial of medical versus surgical termination of pregnancy less than 14 weeks' gestation (TOPS)

OBJECTIVES

To determine the acceptability, efficacy and costs of medical termination of pregnancy (MTOP) compared with surgical termination of pregnancy (STOP) at less than 14 weeks' gestation, and to understand women's decision-making processes and experiences when accessing the termination service.

DESIGN

A partially randomised preference trial and economic evaluation with follow-up at 2 weeks and 3 months.

SETTING

The Royal Victoria Infirmary, Newcastle upon Tyne, UK.

PARTICIPANTS

Women accepted for termination of pregnancy (TOP) under the relevant Acts of Parliament with pregnancies < 14 weeks' gestation on the day of abortion. A further group of women attending contraception and sexual health clinics participated in a discrete choice experiment (DCE).

INTERVENTIONS

STOP: all women > or = 6 weeks' and < 14 weeks' gestation were primed with misoprostol 400 micrograms 2 hours before the procedure. STOP was performed under general anaesthesia using vacuum aspiration. MTOP: all women < 14 weeks' gestation were given mifepristone 200 milligrams orally, returning 36-48 hours later for misoprostol.

OUTCOME MEASURES

Main outcome measure was acceptability of TOP method. Secondary outcome measures included strength of preference by willingness to pay (WTP); distress, using the Impact of Event Scale (IES); anxiety and depression; satisfaction with care; experience of care; frequency and extent of symptoms including self-assessment of pain; clinical effectiveness; and complications. A DCE was used to identify attributes that shape women's preferences for abortion services.

RESULTS

The trial recruited 1877 women, 349 in the randomised arms and 1528 in the preference arms. Of those in the preference arms, 54% chose MTOP. At 2 weeks after the procedure more women having STOP would choose the same method again in the future. Acceptability of MTOP declined with increasing gestational age. The difference in acceptability between STOP and MTOP persisted at 3 months. At 2 weeks after TOP, women in the preference arms were prepared to pay more to have their preferred option. There was no difference in anxiety or depression scores in women having MTOP or STOP. However, women randomised to MTOP had higher scores on subscales of the IES at both 2 weeks and 3 months. There was no difference in IES scores between MTOP and STOP in the preference arm. Women were more likely to be satisfied overall and with technical and interpersonal aspects of care if they had STOP rather than MTOP. Experience of care scores were lower after MTOP in both randomised and preference arms. During admission women undergoing MTOP had more symptoms and reported higher mean pain scores, and after discharge reported more nausea and diarrhoea. There were no differences in time taken to return to work between groups; around 90% had returned to work and normal activity by 2 weeks. Rates of unplanned or emergency admissions were higher after MTOP than after STOP. Overall complication rates were also higher after MTOP, although this only achieved statistical significance in the preference arm. Overall, STOP cost more than MTOP due to higher inpatient standard costs. Even though complication rates were higher with MTOP, it was still more cost-effective. DCE identified three attributes with an almost equal impact on women's preferences: provision of counselling, number of days delay to the procedure, and possibility of an overnight stay.

CONCLUSIONS

MTOP was associated with more negative experiences of care and lower acceptability. Acceptability of MTOP declined with increasing gestational age. MTOP was less costly but also less effective than STOP. The majority of women choosing MTOP were satisfied with their care and found the procedure acceptable. RECOMMENDATIONS FOR FURTHER RESEARCH: An audit of provision of MTOP and STOP in England and Wales is urgently required. Further studies exploring the barriers to offering women the choice of method of TOP are needed, together with research on the acceptability and effectiveness of (1) MTOP and manual VA in pregnancies below 9 weeks' gestation and (2) MTOP and dilatation and evacuation after 14 weeks' gestation.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN07823656.

ER Status and Immune Module Are Central Determinants of HER2 Amplified Infiltrative Breast Carcinoma Prognosis and Pathologic Complete Response

IntroductionGene expression profiling of invasive breast cancer has resulted in highlighting three main categories of breast cancer [luminal, basal, HER2] with very specific features. It has been shown that these subtypes differ in their response to neaoadjuvant systemic treatment, axillary lymph node involvement, metastasis pattern and time to metastasis. The aim of this study was to focus on gene-expression profile analysis of HER2 positive breast carcinoma to assess how the molecular subtype classification applies to the HER2+ve samples; whether subgroups of patients that have different prognosis can be identified and how subgroups can be identified that differ with respect to the likelihood to achieve pathologic complete response (pCR) after neoadjuvant systemic treatment?Materials and MethodWe selected breast carcinomas reported to have a HER2+ve status (IHC and CISH) from patients treated between January 1990 and December 2006 at the Netherlands Cancer Institute. 113 tumor samples were hybridized on the Human Genome Oligo Set Version 3.0 arrays. We identified 205 HER2+ve samples from 4 public microarrays datasets and 33 HER2+ve samples from one public neoadjuvant systemic treatment microarrays dataset.ResultsWe applied the molecular subtype classification to the whole datasets and found major classification instability. 43.3% of the HER2+ve samples were classified as “HER2 subtype”, 26% as “basal-like subtype”, and 21.9% as “luminal-like subtype”. The molecular subtype classification was not correlated to prognosis. Of the prognostic variables tested, only ER status was to the development of distant metastasis (IHC, HR=0.53 [0.36-0.77], p=0.0009). We identified a set of 109 ReporterID's highly enriched in gene ontology annotations link to the Immune Response and correlated to the prognosis of HER2+ve breast carcinoma (Inactivated Immune Module, HR=4.21 [1.94-9.17], logrank pvalue=8.1E-05). The Immune Module Signature was associated with prognosis of the HER2+ve samples in both ER positive and ER negative breast cancer. We validated this Immune Module signature combined with ER status on 205 independent samples.We applied the same classification tree to 33 samples from patients who were assessed for response to neo-adjuvant systemic chemotherapy (Anthracyclin-based) and showed an association between the Immune Module Signature combined with ER status and pCR rate (ER+ve Inactivated Immune Module 12.5% pCR, ER-ve Activated Immune Module 70% pCR, pvalue=0.1).ConclusionWe have shown that HER2+ve breast cancer samples often are not classified as HER2-like by gene expression profiling and that ER (IHC) status determines two major subgroups. We provide new evidence that an immune response relate gene expression classifier has prognostic impact in HER2+ve breast cancer; and that this classifier is potentially correlated to the pCR rate after neoadjuvant systemic treatment in HER2+ve breast cancer.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4037.

Prediction of Prognosis and Treatment Benefit by the Adjuvant! Web-Based Tool: Calibration and Discriminatory Accuracy in 5380 Dutch Breast Cancer Patients

Adjuvant! online (AOL) is a web-based tool that calculates individualized 10-year survival probabilities and predicted benefit of adjuvant systemic therapy. The AOL model was constructed using data from breast cancer patients recorded in the US population-based SEER registry and has not yet been validated in any large European series. European patients may differ from those in the US with regard to prognostic factors and intrinsic tumor characteristics. Therefore the aim of our study was to validate AOL in Dutch patients, investigating both its calibration and discriminatory accuracy.Patients who were treated at the Netherlands Cancer Institute for breast cancer between 1987 and 1998 were selected according to the following criteria: pT1-3, pN0-3, M0, definitive primary surgery, and complete axillary staging. Median follow-up was 11.7 years; &gt;96% of patients had more than 10 years follow-up. Clinicopathological characteristics and adjuvant treatment data were entered into the AOL version 8.0 batch processer, with blinding to outcome.For all 5380 patients included, the 10-year observed overall survival (69.0%) and breast cancer-specific survival (78.6%) rates as compared to the 10-year rates predicted by AOL (69.1% and 77.8%, respectively) were within 1% and not statistically different. Moreover, differences between predicted and observed outcomes were within 2% for most relevant clinicopathological subgroups. Subsets of patients for which there was a discrepancy between the predicted outcomes by AOL and the actual observed outcomes included patients under 40 years, for which both the predicted overall and breast cancer-specific survival were overly optimistic (Pred – Obs: by 4.2% and 4.7% respectively; p&lt;0.05).The concordance(c)-index, which indicates discriminatory accuracy at the individual level, was 0.71 for BCSS in the entire cohort, indicating that AOL performs better than chance. The c-index for a multivariate Cox regression model fitted to the 5380 patients using a backward approach including clinicopathological variables was also 0.71 for BCSS, suggesting AOL optimally incorporates the information in these variables.In order to validate the AOL model, we evaluated both its calibration (goodness of fit) and discriminatory accuracy. Although the latter is rarely examined, it is of paramount importance to justify the use of prognostic models for clinical outcome prediction. We showed that in addition to good calibration, the model was capable of separating individuals with a poor outcome from those with a good outcome with moderate power. In conclusion, AOL accurately predicted 10-year outcomes in this first large scale European validation study and is of use for adjuvant treatment-decision making. Additional inclusion of biological markers in AOL in the future is expected to lead to increased discriminatory accuracy.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4031.

Successful treatment of a large Buschke–Lowenstein tumour with chemo-radiotherapy

We report the case of a patient with a large Buschke–Lowenstein tumour which had previously recurred following local excision. A preferred treatment modality for this rare variant of human papillomavirus has not been clearly defined. Treatment with chemo-radiotherapy in this case resulted in complete resolution of the disease without the need for further surgical intervention.

Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders

BACKGROUND

Microdeletions within chromosome 15q13.3 are associated both with a recently recognised syndrome of mental retardation, seizures, and dysmorphic features, and with schizophrenia.

METHODS AND RESULTS

Based on routine diagnostic testing of approximately 8200 samples using array comparative genomic hybridisation, we identified 20 individuals (14 children and six parents in 12 families) with microdeletions of 15q13.3. Phenotypes in the children included developmental delay, mental retardation, or borderline IQ in most and autistic spectrum disorder (6/14), speech delay, aggressiveness, attention deficit hyperactivity disorder, and other behavioural problems. Both parents were available in seven families, and the deletion was de novo in one, inherited from an apparently normal parent in four, and inherited from a parent with learning disability and bipolar disorder in two families. Of the 14 children, six in five families were adopted, and DNA was available for only one of these 10 biological parents; the deletion was very likely inherited for one of these families with two affected children. Among the unavailable parents, two mothers were described as having mental retardation, another mother as having "mental illness", and one father as having schizophrenia. We hypothesise that some of the unavailable parents have the deletion.

CONCLUSIONS

The occurrence of increased adoption, frequent autism, bipolar disorder, and lack of penetrance are noteworthy findings in individuals with deletion 15q13.3. A high rate of adoption may be related to the presence of the deletion in biological parents. Unconfirmed histories of antisocial behaviours in unavailable biological parents raise the concern that future research may show that deletion 15q13.3 is associated with such behaviours.

Early oxygen uptake recovery following exercise testing in children with chronic chest diseases

The value of exercise testing as an objective measure of disease severity in patients with chronic chest diseases (CCD) is becoming increasingly recognized. The aim of this study was to investigate changes in oxygen uptake (VO2) during early recovery following maximal cardiopulmonary exercise testing (CPXT) in relation to functional capacity and markers of disease severity. Twenty-seven children with CCD (age 12.7 +/- 3.1 years; 17 female) [19 children with Cystic fibrosis (CF) (age 13.4 +/- 3.1 years; 10 female) and 8 with other stable non-CF chest diseases (NON-CF) (age 11.1 +/- 2.2 years; 7 female)] and 27 healthy controls (age 13.2 +/- 3.3 years; 17 female) underwent CPXT on a cycle ergometer. On-line respiratory gas analysis measured VO2 before and during CPXT to peak VO2) (VO2(peak)), and during the first 10 min of recovery. Early VO2 recovery was quantified by the time (sec) to reach 50% of the VO2 (peak) value. Early VO2 recovery was correlated against spirometry [forced expiratory volume in 1 sec (FEV(1)) and forced expiratory flow between 25% and 75% of the forced vital capacity (FEF(25-75))] and aerobic fitness (VO2)(peak)) as a measure of functional capacity. Disease severity was graded in the CF patients by the Shwachman score (SS). Compared to controls, children with CCD demonstrated a significantly reduced VO2(peak) (P = 0.011), FEV(1) (P < 0.001), FEF(25-75) (P < 0.001), and a significantly prolonged early (VO2) recovery (P = 0.024). In the CF patients the SS was significantly correlated with early VO2 recovery (r = -0.63, P = 0.004), FEV(1) (r = 0.72, P = 0.001), and FEF(25-75) (r = 0.57, P = 0.011). In the children with CCD, FEV(1), FEF(25-75), and BMI were not significantly correlated with VO2(peak) or early VO2 recovery. Lung function does not necessarily reflect aerobic fitness and the ability to recover from exercise in these patients. A significant relationship was found between VO2(peak) and early VO2 recovery (r = -0.39, P = 0.044) in the children with CCD, showing that a greater aerobic fitness corresponded with a faster recovery.

A comprehensive analysis of nine prognostic signatures reveals the high classification instability in breast cancer

Abstract #2026

To determine the prognosis of breast cancer patients, clinical and pathological factors are currently employed. Gene expression micro-arrays offer new opportunities to determine individual prognosis. Publications have raised concerns about micro-arrays studies who have the potential to preclude their use in clinical routine. To improve the understanding of gene-expression classifiers we addressed the following issues: 1) Is the performance similar between independent classifiers? 2) Is proliferation a common biological theme that represents various signatures? 3) Are there other enriched pathways among signatures with prognostic ability?&#x2028; Methods:&#x2028; On 6 public datasets we applied the 76-gene signature; the Molecular subtypes; the Chromosomal Instability Signature; the Wound Signature; the Invasiveness Gene Signature; the Molecular Prognosis Index; and the Genomic Grade Index. Survival, predictive accuracy and overlap analyses were performed. We created enlarged signatures by including all probes with significant correlation to at least one of the genes in the original signatures. We gathered a collection of gene sets from four databases (GO, KEGG, Reactome, MSDB). For each signature, we evaluated whether specific gene sets (modules) are overrepresented. We tested the prognosis ability of each of them.&#x2028; Results:&#x2028; The survival and predictive accuracy analyses gave similar results for each of the 9 signatures. They all added significant information to a multivariate model including standard pathological and clinical criteria. Nevertheless, we showed that none of these signatures were able to identify good and poor prognosis patients when applied to samples with intrinsically poor prognosis features (Positive Lymph Node, Negative Estrogen Receptor, High Grade). Conversely they identified good and poor prognosis patients when applied to samples with intrinsically good prognosis features (Negative LN, Positive ER Low Grade). The overlap analysis showed a low agreement between the signatures. 50% of the samples had almost one discordant classification result out of the 9 classifiers tested. The intersection of the signatures revealed a set of proliferation genes. The signatures were build on 10 different gene ontology modules with prognostic ability.&#x2028; Conclusion:&#x2028; This study underlines the need of large prospective validation studies of gene expression signatures. Further computational intelligence and system biology studies would be held to determine the best way to use these classifiers in clinical routine.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2026.

Exploring the performance of molecular rectifiers: limitations and factors affecting molecular rectification

There has been significant work investigating the use of molecules as nanoscale rectifiers in so-called "molecular electronics". However, less attention has been paid to optimizing the design parameters of molecular rectifiers or to their inherent limitations. Here we use a barrier tunneling model to examine the degree of rectification that can be achieved and to provide insight for the design and development of molecules with optimum rectification responses.

Functional eccentric-concentric ratio of knee extensors and flexors in pre-pubertal children, teenagers and adult males and females

The purpose of this study was to examine the age and sex associated differences in the eccentric/concentric functional ratio for the knee. Isokinetic concentric and eccentric knee extension and flexion was measured at 0.52 rad x s (-1) and 3.14 rad x s (-1) in 121 subjects. Other than mass there were no significant age-by-sex interaction effects for all variables examined. A significant velocity-by-age group effect was demonstrated for ECC (KF)/CON (KE) with higher ratios at 3.14 compared to 0.52 rad x s (-1). Females' CON (KF)/ECC (KE) was significantly lower than males at both velocities. Adults demonstrated significantly lower CON (KF)/ECC (KE) than the teenagers at 0.52 rad x s (-1) and lower than the prepubertal and teenager groups at 3.14 rad x s (-1). However, for ECC (KF)/CON (KE) at 3.14 rad x s (-1), prepubertal ratios were significantly lower than teenagers and adults. The results of the current study suggest that functional rather than conventional ratio should be used when examining knee stability. During fast velocity movements, prepubertal children have a lower capacity for generating eccentric compared to concentric torque. The lower CON (KF)/ECC (KE) ratio in adults appears to be due to a greater ability to generate large eccentric torques at all slow and fast movement velocities. The lower CON (KF)/ECC (KE) ratio in females is a product of lower concentric torque as opposed to high eccentric torque producing capability as previously thought.

Effects of age and recovery duration on performance during multiple treadmill sprints

The aim of this study was to investigate the effects of age and recovery duration on performance during multiple treadmill sprints. Twelve boys (11.7 +/- 0.5 y) and thirteen men (22.1 +/- 2.9 y) performed ten consecutive 10-s sprints on a non-motorised treadmill separated by 15-s (R15) and 180-s (R180) passive recovery intervals. Mean power output (MPO), mean force output (MFO), running velocity, step length, and step rate were calculated for each sprint. Capillary blood samples were drawn from the fingertip at rest and 3 min after the tenth sprint to measure the lactate accumulation (Delta [La]). With R15, all mechanical parameters decreased significantly less in the boys than in the men over the ten sprints (MPO: - 28.9 vs. - 47.0 %, MFO: - 13.1 vs. - 25.6 %, running velocity: - 18.8 vs. - 29.4 %, p < 0.001, respectively). With R180, all mechanical values remained unchanged in the boys. In the men, MPO and MFO significantly decreased over the ten sprints (- 7.8 % and - 4.6 %, p < 0.05, respectively). The running velocity, however, did not decrease because the decrease in step rate (p < 0.001) was compensated by an increase in step length. For either recovery interval, Delta [La] values were higher in the men compared to the boys (R15: 12.7 vs. 7.7 mmol . L (-1), p < 0.001, R180: 10.7 vs. 7.7 mmol . L (-1), p < 0.05). To conclude, the boys maintained more easily their running performance than the men during repeated treadmill sprints with R15. Three-minute recovery periods were sufficient in the boys to repeat short running sprints without substantial fatigue. Despite the decrease in power and force outputs with R180, the young men were able to maintain their running velocity during the test.

Measurement of maximal muscle cross-sectional area of the elbow extensors and flexors in children, teenagers and adults

The aims of this study were to examine age and sex differences in elbow extensor and flexor anatomical muscle cross-sectional area (mCSA) measured by magnetic resonance imaging (MRI) and the location of maximal mCSA as a percentage of the distance from the distal to the proximal end of the humerus. Ninety-five individuals spread across the age groups 9 - 10 years, 16 - 17 years and ?21 years participated in the study. Muscle cross-sectional area derived from the manual MRI tracing proved to be highly reliable in terms of limits of agreement (-2.5 to 1.5 cm(2)) and the intraclass correlation coefficient (ICC = 0.998). A sex-by-age group analysis of variance revealed significant effects (P < 0.01) of sex, group and a sex-by-group interaction, the latter reflecting a greater increase in males than females of upper arm mCSA from childhood to adulthood. Extensor mCSA was more proximal (55 +/- 6%) than that of the flexors (28 +/- 6%). A significant effect (P < 0.01) of group was found for location of maximal extensor mCSA, reflecting its more distal position with increasing age. Measurements of muscle size should be made at the individually determined position of maximal mCSA if interpreting data collected during growth and maturation, especially if the muscle group of interest is the elbow extensors and if different age groups are being monitored.

Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients

Folate is required for DNA synthesis, repair and methylation. Low folate status has been implicated in carcinogenesis, possibly as a result of higher rate of genetic damage. The aim of this study is to compare folate status and levels of DNA damage between breast cancer and benign breast disease control patients. Fasting blood samples from 64 histologically confirmed untreated breast cancer patients (mean age 57 years) and 30 benign breast disease control patients (mean age 51 years) were obtained. Red cell folate (RCF) and plasma homocysteine were measured. Mononuclear cells (MNC) were isolated for genetic damage analysis using the basic alkaline comet assay. Results are expressed as tail moment. Data were log transformed as appropriate before analysis for normalisation purposes. The geometric mean (95% confidence interval) of RCF (ng ml⁻¹) in breast cancer patients was 339.07 (333.3–404.6) vs 379.5 (335.8–505.2) in control patients (P=0.24). Corresponding plasma homocysteine concentrations (μmol l⁻¹) were 11.9 (10.6–16.4) vs 10.1 (9.3–11.9) (P=0.073), respectively. The mean tail moment (s.d.) of DNA damage in MNC of breast cancer patients detected by the basic comet assay was 1.4 (0.66) vs –0.17 (0.79) in controls (P<0.0001, t-test), the modified comet assay ‘endonuclease III (Endo III)’ was 1.7 (0.70) vs 0.86 (0.81) (P<0.0001, t-test), and the modified comet assay ‘formamidopyrimidine glycosylase (FPG)’ was 1.6 (0.62) vs 0.99 (0.94) (P<0.0001, t-test). There was a significant negative correlation between RCF levels and DNA damage detected by modified comet assay ‘FPG’ (Pearson Correlation Coefficient r²=−0.26, P=0.02) and DNA damage was found to be significantly higher in MNC of breast cancer patients compared to benign breast disease control patients. Breast cancer patients tended to have lower RCF levels and higher levels of plasma homocysteine, but these differences were not significant. The study provides preliminary evidence that reduced folate status may be implicated in the aetiology of breast cancer perhaps by increasing the in vivo level of genetic instability.

Does aerobic fitness influence microvascular function in healthy adults at risk of developing Type 2 diabetes?

AIM

To investigate whether aerobic fitness is associated with skin microvascular function in healthy adults with an increased risk of developing Type 2 diabetes.

METHODS

Twenty-seven healthy normal glucose-tolerant humans with either a previous diagnosis of gestational diabetes or having two parents with Type 2 diabetes and 27 healthy adults who had no history of diabetes were recruited. Maximal oxygen uptake was assessed using an incremental exercise test to exhaustion. Skin microvascular function was assessed using laser Doppler techniques as the maximum skin hyperaemic response to a thermal stimulus (maximum hyperaemia) and the forearm skin blood flow response to the iontophoretic application of acetylcholine (ACh) and sodium nitroprusside.

RESULTS

Maximal oxygen uptake was not significantly different in the 'at-risk' group compared with healthy controls. Maximum hyperaemia was reduced in those 'at risk' (1.29 +/- 0.30 vs. 1.46 +/- 0.33 V, P = 0.047); however, the peak response to acetylcholine or sodium nitroprusside did not differ in the two groups. A significant positive correlation was demonstrated between maximal oxygen uptake and maximum hyperaemia (r = 0.52, P = 0.006 l/min and r = 0.60, P = 0.001 ml/kg/min) and peak ACh response (r = 0.40, P = 0.04 l/min and r = 0.47, P = 0.013 ml/kg/min) in the 'at-risk' group when expressed in absolute (l/min) or body mass-related (ml/kg/min) terms. No significant correlations were found in the control group.

CONCLUSIONS

In this 'at-risk' group with skin microvascular dysfunction maximal oxygen uptake was not reduced compared with healthy controls. However, in the 'at-risk' group alone, individuals with higher levels of aerobic fitness also had better microvascular and endothelial responsiveness.

Reliability of heart rate variability measures at rest and during light exercise in children

OBJECTIVES

To investigate the reliability of heart rate variability (HRV) measures at rest and during light exercise in children.

METHODS

Short term (five minute) HRV was assessed in 12 children (11-12 years of age). HRV measures were collected at rest with the children supine, breathing at 12 breaths/min, and during exercise on a cycle ergometer while exercising at 25% of peak oxygen uptake. Both resting and exercise data were collected twice from each child.

RESULTS

Intraclass correlation coefficients were low to moderate for most measures with wide confidence intervals for each variable in both resting and exercise conditions. Random variation (typical error) within repeated measurements ranged from 31% to 187%.

CONCLUSIONS

These preliminary findings suggest that HRV measures are unreliable at rest and during light exercise in children aged 11-12 years. Tighter control of extraneous influences is recommended.

Bayesian Inference of Nanoparticle-Broadened X-Ray Line Profiles

A single-step, self-contained method for determining the crystallite-size distribution and shape from experimental x-ray line profile data is presented. It is shown that the crystallite-size distribution can be determined without invoking a functional form for the size distribution, determining instead the size distribution with the least assumptions by applying the Bayesian/MaxEnt method. The Bayesian/MaxEnt method is tested using both simulated and experimental CeO2 data, the results comparing favourably with experimental CeO2 data from TEM measurements.

Cardiovascular responses to submaximal treadmill running in 11 to 13 year olds

The influence of age, sex, maturity, body size and body fatness on cardiac output (Q) and stroke volume (SV) during treadmill running at 2.22 m x s(-1) was examined longitudinally. Mass, stature, triceps and subscapular skinfold thickness, and oxygen uptake (VO2) were recorded and Q was estimated using the CO2 rebreathing technique on each of three annual measurement occasions. Maturity was assessed using the indices for pubic hair described by Tanner. At the onset, subjects were 11.3 (0.4) y of age and data were available from a total of 274 Q determinations with equal numbers from boys and girls. Age-, sex- and maturity-associated changes in Q and SV adjusted for differences in body size and fatness were examined using multilevel regression modelling within an allometric framework. Changes in Q in both sexes were essentially in direct proportion to body surface area but, even with anthropometric variables controlled for, girls demonstrated a lower SV than boys, which was compensated for by a higher heart rate (HR) at each observation.

CONCLUSION

At a given level of submaximal exercise over the age range 11-13 y Q is directly related to body size in both sexes. With body size and fatness controlled for, boys have greater SVs than girls when exercising at the same absolute VO2, Q and treadmill running speed. Age and maturation do not exert independent effects on either Q or SV.

Longitudinal changes in isokinetic leg strength in 10-14-year-olds

This study used multilevel regression modelling to longitudinally investigate the influences of age, sex, body size, skinfold thicknesses and maturity on the development of isokinetic knee extension and flexion on eight occasions over a 4-year period. Forty-one subjects (20 boys and 21 girls) were measured and 295 isokinetic leg strength tests and associated measures were successfully completed. Subjects were aged 10.0 +/- 0.3 years at the onset of the study. Stature, body mass, triceps and subscapular skinfold thicknesses, and sexual maturation (according to pubic hair development) were assessed at each test occasion. Isokinetic concentric knee extension and flexion of the dominant leg were determined to elicit maximal peak extension (PET) and flexion torque (PFT). Statistical significance was accepted at p < 0.05. Multilevel regression modelling indicated that stature and mass were significant predictors of both PET and PFT. Age and maturity were non-significant explanatory variables once stature and mass had been accounted for. Skinfold thickness exerted a significant negative effect independent of mass and stature on PFT but not PET. At test occasion 8, cross-sectional areas (CSAs) of the knee extensors (ExCSA) and flexors (FlexCSA) were determined using magnetic resonance imaging on 23 boys and 14 girls and examined as predictors of isokinetic leg strength. There were no significant sex-related differences in PET or PFT. Pearson product moment correlation coefficients indicated a significant relationship between ExCSA and PET and FlexCSA and PFT for both boys and girls. Analysis of covariance (ANCOVA) demonstrated that ExCSA and FlexCSA were significant explanatory variables for PET and PFT, respectively, but became non-significant once stature and mass had been introduced into the analysis. To conclude, there were no significant sex differences in PET or PFT between the ages of 10 and 14 years and the development of PET and PFT could be accounted for by the increase in stature and mass. Age, maturity and thigh muscle CSA were all non-explanatory variables in the production of PET and PFT once body size had been controlled for.

Peak oxygen uptake in relation to growth and maturation in 11- to 17-year-old humans

This study used multilevel modelling to examine peak oxygen uptake (VO2peak) during growth and maturation. Body mass, stature, triceps and subscapular skinfold thicknesses, blood haemoglobin concentration, and VO2peak of boys and girls, [mean (SD)] aged 11.1 (0.4) years at the onset of the study, were measured at ages 11, 12, 13 and 17 years. Sexual maturation was assessed on the first three occasions and was assumed to be Tanner stage 5 at 17 years. The analysis was founded on 388 VO2peak determinations from 132 children. The initial model revealed mass, stature and age as significant explanatory variables of VO2peak with an additional positive effect for stage of maturity. Girls' values were significantly lower than those of boys and a significant age-by-sex interaction described a progressive divergence in boys' and girls' VO2peak. The introduction of skinfold thicknesses produced a model with an improvement in fit. The stature term was negated and the mass exponent almost doubled. The sex and age-by-sex terms were reduced but remained significant. Many of the observed maturity effects were explained with stage 5 becoming non-significant. Blood haemoglobin concentration was a nonsignificant parameter estimate in both models. Fat-free mass was the dominant influence on the growth of VO2peak but the multilevel regression models demonstrated that, with body size and fatness allowed for, VO2peak increased with age and maturation in both sexes.

Short term power output in relation to growth and maturation

OBJECTIVE

To examine short term power output during growth and maturation using a multilevel modelling approach.

METHODS

Body mass, stature, and triceps and subscapular skinfold thicknesses of boys and girls, aged 12.2 (0.4) years (mean (SD)) at the onset of the study, were measured at age 12, 13, and 17 years. Sexual maturation, classified according to Tanner's stage of pubic hair development, was assessed on the first two occasions and assumed to be stage 5 at 17 years. Peak power (PP) and mean power (MP) were assessed on each occasion using the Wingate anaerobic test.

RESULTS

Initial models, founded on 417 determinations of short term power output, identified body mass, stature, and age as significant explanatory variables of both PP and MP. The values for girls were significantly lower than those for boys, and a significant age by sex interaction described a progressive divergence in the MP of boys and girls. The introduction of sum of two skinfold thicknesses produced a model with an improvement in fit as indicated by a significant change in log likelihood. The stature term was negated and the body mass term increased. The age and sex terms were reduced but remained significant. The age by sex interaction term remained a significant explanatory variable for MP. Maturity effects were non-significant additional explanatory variables in all models of power output.

CONCLUSION

The values of PP and MP for boys are higher than those for girls, and, for MP, sex differences increase with age. Body mass and skinfold thicknesses are significant influences on both PP and MP, but age exerts a positive but non-linear effect on power output independent of body size and fatness.

Changes in short-term power output in 10- to 12-year-olds

In this study, we used multi-level regression modelling to assess the influence of age, sex, body size, skinfold thicknesses, maturity, thigh muscle volume and isokinetic leg strength on the development of load- and inertia-adjusted peak (1 s) and mean power (30 s) determined using the Wingate anaerobic test. Fifteen males and 19 females were measured twice, first aged 10.0 +/- 0.3 years and then aged 11.8 +/- 0.3 years. Initial models identified body mass and height as significant explanatory variables (P < 0.05) for peak power and mean power, with an additional age effect for the former. No significant differences between the sexes or maturity effects were observed for either peak or mean power (P > 0.05). The introduction of sum of skinfolds improved the fit of the model and rendered the height term non-significant for both peak and mean power (P> 0.05). An age effect became apparent for mean power. When isokinetic leg strength and thigh muscle volume were entered into the model, the latter exerted a significant effect on both peak and mean power (P< 0.05), whereas isokinetic leg strength was not a significant explanatory variable for either (P> 0.05). In conclusion, thigh muscle volume exerts a positive influence on young people's short-term power output, which is additional to the effects of body mass, sum of skinfolds and age.

Effect of training on peak oxygen uptake and blood lipids in 13 to 14-year-old girls

The aim of this study was to investigate the effects of exercise training on the peak oxygen uptake (peak VO2) and blood lipid profile of 13 to 14-y-old postmenarcheal girls. Treadmill determined peak VO2, total cholesterol, high density lipoprotein cholesterol, low density cholesterol, and triglycerides were the outcome measures assessed at baseline and following exercise training. Twenty girls completed a 20-wk programme of exercise training which involved maintaining the heart rate at 75-85% maximum for 20 min, three times per week. Heart rate was rigorously monitored using telemetry throughout each training session. Eighteen girls acted as the control group. There were no significant (p > 0.05) changes in the outcome measures following the training programme.

CONCLUSIONS

These findings suggest that exercise training of this frequency, intensity and duration for a period of 20 wk has no significant effect on either the peak VO2 or blood lipid and lipoprotein profile of normolipidaemic, postmenarcheal girls.

X-ray diffraction line broadening from thermally deposited gold films

Diffraction profiles were analysed from thermally deposited 111-oriented gold films, ranging in thickness from 300 to 1900 Å. The data were collected using the high-resolution powder diffractometer on beamline BM16 at the European Synchrotron Research Facility (ESRF) set at a wavelength of 0.3507 Å. The profiles were measured under conventional symmetric θ–2θ reflection conditions and by asymmetric transmission diffraction to ensure that only crystallites oriented normal to the substrate contribute to the diffraction. An analysis of the instrument profile shape of the diffractometer was undertaken using the SRM 660 LaB6line profile standard. A parallel study of the films using atomic force microscopy and transmission electron microscopy was also undertaken to provide information on the dimensions of the crystallite columns in the films and the presence of dislocations. All the films displayed diffraction broadening arising from both crystallite-size effects and dislocation-induced strain effects. Analysis of the magnitude and anisotropy of the dislocation-induced broadening withhklindicates that the dislocations have a mixed screw/edge character and tend to form primarily on (111) slip planes parallel to the substrate at densities of ∼1015to 1016 m−2.